MAPK3 and prostate carcinoma: Studies have shown that Erk1/2 could exhibit abnormal expression or enhanced activity in various tumor tissues such as liver cancer and prostate cancer, suggesting that the abnormal regulation of Erk is closely related to the occurrence and development of tumors [41,42].